Abbott Laboratories surpassed Wall Street’s quarterly profit expectations, buoyed by robust demand for medical procedures. Increased sales of its medical devices, particularly glucose-monitoring products, contributed to the positive results. The company reported an adjusted first-quarter profit of 98 cents per share, surpassing analysts’ estimates of 95 cents per share. Additionally, Abbott raised the lower end of its full-year profit forecast to $4.55-$4.70 per share, compared to the previous $4.50 per share. Analysts had anticipated a profit of $4.60 per share. Abbott’s performance underscores the strong demand for its medical devices and its optimistic outlook for the future.